Antonino Passaniti

University of Maryland, Baltimore — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

41h-index6.7kcitations104works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(19), Angiogenesis and VEGF in Cancer(15), Cell Adhesion Molecules Research(15), Glycosylation and Glycoproteins Research(14), Galectins and Cancer Biology(9)

Publications104 total

A Novel Approach to Potentially Improving Soft-Tissue Sarcoma Survival: Prophylactic Lung Radiotherapy Inhibits Growth of Lung Metastases and Prolongs Survival in a Murine Soft-Tissue Sarcoma Model
Cureus·2024Open Access
Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia
International Journal of Molecular Sciences·2024Open Access
Altered sialidase expression in human myeloid cells undergoing apoptosis and differentiation
Scientific Reports·2022· 11 citedOpen Access
Targeting mitochondrial metabolism for metastatic cancer therapy
Molecular Carcinogenesis·2022· 45 citedOpen Access
Matrigel: history/background, uses, and future applications
Journal of Cell Communication and Signaling·2021· 128 citedOpen Access
Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells
Cancers·2021· 16 citedOpen Access
Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis
Oncotarget·2020· 19 citedOpen Access
Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes
Annals of Translational Medicine·2019· 4 citedOpen Access
Abstract 794: Inhibition of mitochondrial metabolism by a novel agent targeting RUNX2-DNA binding in breast cancer
Cancer Research·2019
Abstract 794: Inhibition of mitochondrial metabolism by a novel agent targeting RUNX2-DNA binding in breast cancer
Molecular and Cellular Biology / Genetics·2019
Identification of Cross Talk between FoxM1 and RASSF1A as a Therapeutic Target of Colon Cancer
Cancers·2019· 17 citedOpen Access
Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity
Oncotarget·2017· 28 citedOpen Access
Roles of RUNX in Hippo Pathway Signaling
Advances in experimental medicine and biology·2017· 37 citedOpen Access
Metabolic targets for potential prostate cancer therapeutics
Current Opinion in Oncology·2016· 40 citedOpen Access
A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-κB regulates head and neck squamous cell carcinoma proliferation
Oncotarget·2016· 69 citedOpen Access
Abstract P5-05-02: Regulation of glucose metabolism by the RUNX2 transcription factor has a negative impact on mitochondrial function in breast cancer cells
Cancer Research·2016
RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells
Oncotarget·2015· 36 citedOpen Access
The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells
Journal of Cellular Biochemistry·2015· 77 citedOpen Access
α<sub>1</sub>-Acid glycoprotein disrupts capillary-like tube formation of human lung microvascular endothelia
Experimental Lung Research·2014· 2 cited
Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells
Microvascular Research·2014· 26 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Роберто Пили(8), Simeon E. Goldblum(8), Sang Won Hyun(5), Joan Chang(4), Maurizio C. Capogrossi(4), Paul Shapiro(4), Anguo Liu(4), Michele Vítolo(4), Edward G. Lakatta(3), Daniel J. Angelini(3), Chunlin Yang(3), Corrado Cirielli(3), Erik P. Lillehoj(3), Alan S. Cross(3), Jessica L. Brusgard(3), Keli J. Renoud(3), Lixin Sun(2), Joseph A. Haney(2), Rebecca Pauly(2), Robert E. Monticone(2)